A suite of engineered mice for interrogating psychedelic drug actions

Read full text
Authors: Yi-Ting Chiu, Ariel Y. Deutch, Wei Wang, Gavin P. Schmitz, Karen Huang, D. Dewran Koçak, Pierre Llorach, Kasey Bowyer, Bei Liu, Noah Sciaky, Kunjie Hua, Chongguang Chen
+10 more Sarah E. Mott, Jesse K. Niehaus, Jeffrey F. DiBerto, Justin G. English, Jessica J. Walsh, Grégory Scherrer, Melissa A. Herman, Zhuhao Wu, William C. Wetsel, Bryan L. Roth
Cited by: 16
References: 115

Abstract

ABSTRACT Psychedelic drugs like lysergic acid diethylamide (LSD) and psilocybin have emerged as potentially transformative therapeutics for many neuropsychiatric diseases, including depression, anxiety, post-traumatic stress disorder, migraine, and cluster headaches. LSD and psilocybin exert their psychedelic effects via activation of the 5-hydroxytryptamine 2A receptor (HTR2A). Here we provide a suite of engineered mice useful for clarifying the role of HTR2A and HTR2A-expressing neurons in psychedelic drug actions. We first generated Htr2a -EGFP-CT-IRES-CreERT2 mice (CT:C-terminus) to independently identify both HTR2A-EGFP-CT receptors and HTR2A-containing cells thereby providing a detailed anatomical map of HTR2A and identifying cell types that express HTR2A. We also generated a humanized Htr2a mouse line and an additional constitutive Htr2A -Cre mouse line. Psychedelics induced a variety of known behavioral changes in our mice validating their utility for behavioral studies. Finally, electrophysiology studies revealed that extracellular 5-HT elicited a HTR2A-mediated robust increase in firing of genetically-identified pyramidal neurons--consistent with a plasma membrane localization and mode of action. These mouse lines represent invaluable tools for elucidating the molecular, cellular, pharmacological, physiological, behavioral, and other actions of psychedelic drugs in vivo .

Fields of Study & Subjects

Photoreceptor and optogenetics research Nicotinic Acetylcholine Receptors Study Neuroscience and Neuropharmacology Research

Publication details

Journal / source
Nature Neuroscience
Publisher
Springer Science and Business Media LLC
Volume
29
Issue
9
Pages
2341–2354
Publication date
6 August 2026
Language
EN